Placebo-Controlled Study To Evaluate Efficacy And Safety Of Ly3041658 In Adults With Moderate-To-Severe Hidradenitis Suppurativa
Posted Date: Jun 14, 2021
- Investigator: Debra Breneman
- Specialties:
- Type of Study: Drug
This study is being conducted to determine if treatment with LY3041658 is superior to placebo (no active drug) in inducing positive clinical response in adult with moderate-to-severe hidradenitis suppurativa (HS). LY3041658 is a monoclonal antibody that binds to and neutralizes factors involved in HS inflammation that is critical in the pathology of the disease. Blocking these factors is expected to ameliorate symptoms and pain associated with the disease. LY3041658 or placebo are given intravenously every two weeks. The study has approximately 51 weeks of duration. The treatment period has a 16-week duration, followed by a 20-week period of single-group open-label in which all participants will receive LY3041658. Use of topical antiseptics will be required for the duration of the study.
Criteria:
Eligible Participants Should Have 18 To 65 Years Of Age, Sign The Informed Consent, Have A Diagnosis Of Hs For At Least 6 Months, Have Hs Lesions Distributed On The Two Sides Of The Body (Left And Right) , Some Other Conditions May Exclude Participants . Ved Any Biological Agent)
Keywords:
Hidradenitis Suppurativa, Acne Inversa, Inflamed Lesions
For More Information:
Jordan Sambrookes
(513) 558-0951
perryj8@ucmail.uc.edu